Literature DB >> 22147199

Combination treatment with dihydrotanshinone I and irradiation enhances apoptotic effects in human cervical cancer by HPV E6 down-regulation and caspases activation.

Yintao Ye1, Wenqing Xu, Wei Zhong, Yajing Li, Chen Wang.   

Abstract

The aim of this study was to investigate the effect of dihydrotanshinone I (DI) in inhibiting the growth of human cervical cancer cells both in vitro and in vivo, and molecular targets in HeLa cells when treated by DI or irradiation with or without being combined. In this study, MTT, clonogenic assay, flow cytometry, and Western blotting were performed to assess the effect of treatment on cells. After treatment with IR, DI, and DI + IR, the apoptosis was 5.8, 13.3 and 22.5% (P < 0.05 vs. control), respectively. Clonogenic assay revealed that the survival of irradiated HeLa cell was significantly reduced by DI treatment. Combination treatment with IR and DI could down-regulate HPV E6 gene expression. Effect of DI on up-regulation of p21 expression and down-regulation of cyclin B1, p34(cdc2) expression in irradiated HeLa cell was concomitant with cell cycle arrest in G(2) phase. The significant increase in caspase-3 activity was also observed in the combination treatment. When HeLa cells were grown as xenografts in nude mice, combination treatment with DI and IR induced a significant decrease in tumor growth, and without signs of general or organ toxicity. These data suggest DI should be tested as the radiosensitizer in vitro and in vivo, which has potential in the treatment of human cervical cancer.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22147199     DOI: 10.1007/s11010-011-1171-0

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  45 in total

Review 1.  Programmed cell death: alive and well in the new millennium.

Authors:  S H Kaufmann; M O Hengartner
Journal:  Trends Cell Biol       Date:  2001-12       Impact factor: 20.808

Review 2.  Chemoradiation: A new approach for the treatment of cervical cancer.

Authors:  V Loizzi; G Cormio; G Loverro; L Selvaggi; P J Disaia; F Cappuccini
Journal:  Int J Gynecol Cancer       Date:  2003 Sep-Oct       Impact factor: 3.437

3.  Glutathione disulfide induces apoptosis in U937 cells by a redox-mediated p38 MAP kinase pathway.

Authors:  Giuseppe Filomeni; Giuseppe Rotilio; Maria Rosa Ciriolo
Journal:  FASEB J       Date:  2002-11-01       Impact factor: 5.191

4.  Enhancement of radiation response in human cervical cancer cells in vitro and in vivo by arsenic trioxide (As2O3).

Authors:  Yong Jin Chun; In Chul Park; Myung Jin Park; Sang Hyeok Woo; Seok Il Hong; Hee Yong Chung; Tae Hwan Kim; Yun Sil Lee; Chang Hun Rhee; Su Jae Lee
Journal:  FEBS Lett       Date:  2002-05-22       Impact factor: 4.124

Review 5.  Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix.

Authors:  J Green; J Kirwan; J Tierney; C Vale; P Symonds; L Fresco; C Williams; M Collingwood
Journal:  Cochrane Database Syst Rev       Date:  2005-07-20

6.  Protective effects of Danshensu from the aqueous extract of Salvia miltiorrhiza (Danshen) against homocysteine-induced endothelial dysfunction.

Authors:  K Chan; S H Chui; D Y L Wong; W Y Ha; C L Chan; R N S Wong
Journal:  Life Sci       Date:  2004-11-12       Impact factor: 5.037

7.  Upregulation and activation of caspase-3 or caspase-8 and elevation of intracellular free calcium mediated apoptosis of indomethacin-induced K562 cells.

Authors:  Guang-sen Zhang; Guang-biao Zhou; Chong-wen Dai
Journal:  Chin Med J (Engl)       Date:  2004-07       Impact factor: 2.628

8.  Combined action of celecoxib and ionizing radiation in prostate cancer cells is independent of pro-apoptotic Bax.

Authors:  René Handrick; Ute Ganswindt; Heidrun Faltin; Barbara Goecke; Peter T Daniel; Wilfried Budach; Claus Belka; Verena Jendrossek
Journal:  Radiother Oncol       Date:  2008-11-27       Impact factor: 6.280

Review 9.  Nuclear factor-kappa B as a predictor of treatment response in breast cancer.

Authors:  Amit K Garg; Gabriel N Hortobagyi; Bharat B Aggarwal; Aysegul A Sahin; Thomas A Buchholz
Journal:  Curr Opin Oncol       Date:  2003-11       Impact factor: 3.645

10.  Heyneanol A induces apoptosis via cytochrome c release and caspase activation in human leukemic U937 cells.

Authors:  Eun-Ok Lee; Byoung-Mog Kwon; Gyu-Yong Song; Chan-Hee Chae; Hyung-Min Kim; In-Sop Shim; Kyoo-Seok Ahn; Sung-Hoon Kim
Journal:  Life Sci       Date:  2004-03-19       Impact factor: 5.037

View more
  4 in total

1.  The herbal compound cryptotanshinone restores sensitivity in cancer cells that are resistant to the tumor necrosis factor-related apoptosis-inducing ligand.

Authors:  Anfernee Kai-Wing Tse; Ka-Yu Chow; Hui-Hui Cao; Chi-Yan Cheng; Hiu-Yee Kwan; Hua Yu; Guo-Yuan Zhu; Yiu-Cheong Wu; Wang-Fun Fong; Zhi-Ling Yu
Journal:  J Biol Chem       Date:  2013-08-28       Impact factor: 5.157

2.  Regulation of HuR structure and function by dihydrotanshinone-I.

Authors:  Preet Lal; Linda Cerofolini; Vito Giuseppe D'Agostino; Chiara Zucal; Carmelo Fuccio; Isabelle Bonomo; Erik Dassi; Stefano Giuntini; Danilo Di Maio; Vikalp Vishwakarma; Ranjan Preet; Sha Neisha Williams; Max S Fairlamb; Rachel Munk; Elin Lehrmann; Kotb Abdelmohsen; Saioa R Elezgarai; Claudio Luchinat; Ettore Novellino; Alessandro Quattrone; Emiliano Biasini; Leonardo Manzoni; Myriam Gorospe; Dan A Dixon; Pierfausto Seneci; Luciana Marinelli; Marco Fragai; Alessandro Provenzani
Journal:  Nucleic Acids Res       Date:  2017-09-19       Impact factor: 16.971

Review 3.  Tanshinones: sources, pharmacokinetics and anti-cancer activities.

Authors:  Yong Zhang; Peixin Jiang; Min Ye; Sung-Hoon Kim; Cheng Jiang; Junxuan Lü
Journal:  Int J Mol Sci       Date:  2012-10-22       Impact factor: 5.923

4.  Nip the HPV encoded evil in the cancer bud: HPV reshapes TRAILs and signaling landscapes.

Authors:  Talha Abdul Halim; Ammad Ahmad Farooqi; Farrukh Zaman
Journal:  Cancer Cell Int       Date:  2013-06-17       Impact factor: 5.722

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.